Pharmachal Health Group - Highlights from the first quarter of 2021

March 2021 update

This article is from Unspecified for Health Care, Medical & Biotech


During the Quarter Pharmachal Health Group:

  • Directed the contract manufacturer to initiate the third and final commercial-scale batch of NOPAYNE, the last ‘step up’ batch required before submission to the TGA. This is a massive milestone for the company and paves the way to launch of NOPAYNE in the second half of the year.
  • Initiated orders for three over-the-counter dermal products, allowing PHG to take them to market in the next 6 – 8 weeks.
  • Cemented its equity position in NS Technologies, coming to terms and making a down-payment to acquire 90% of the related company holding the NDDS patents.
  • Further developed its relationship with a Canadian pharma group to explore co-development and marketing of products. Licencing agreements have been discussed to have products manufactured under licence in Canada for the North American market.
  • Deepened ongoing discussions with a Swiss / South African company to register the anti-viral flu / Covid-19 drug Triazavirin™ - Riamilovir – TZV in Australia.

Please download the full update via the link below. 

Related Attachments

March 19th, 2021

Pharmachal | March 2021 update ( 118.74 KB )

Related News & Products

  • Pharmachal's Nopayne product receives compelling independent results
    January 19th, 2021
    Pharmachal's Nopayne product receives compelling independent results